Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Neurology
|
June 1, 2026
Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals
Calvin Trieu, Ellen Dicks, Diederick de Leeuw, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 21, 2021
Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients
Rens Zonneveld, Suzanne Jurriaans, Tom van Gool, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Biomarkers
Sinthujah Vigneswaran, Inge M W Verberk, Lynn Boonkamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 13, 2026
Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants
Matthijs W J de Waal, Sven J van der Lee, Melanie Lunding, et al.
Nature Communications
|
January 29, 2025
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Katharina Bolsewig, Eline A J Willemse, Pascual Sánchez-Juan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 23, 2025
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study
James D Doecke, Giovanni Bellomo, Lisa Vermunt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 28, 2022
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition
Pratishtha Chatterjee, Lisa Vermunt, Brian A Gordon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Neurology
|
June 1, 2026
Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals
Calvin Trieu, Ellen Dicks, Diederick de Leeuw, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 21, 2021
Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients
Rens Zonneveld, Suzanne Jurriaans, Tom van Gool, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Biomarkers
Sinthujah Vigneswaran, Inge M W Verberk, Lynn Boonkamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 13, 2026
Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants
Matthijs W J de Waal, Sven J van der Lee, Melanie Lunding, et al.
Nature Communications
|
January 29, 2025
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Katharina Bolsewig, Eline A J Willemse, Pascual Sánchez-Juan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 23, 2025
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study
James D Doecke, Giovanni Bellomo, Lisa Vermunt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 28, 2022
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition
Pratishtha Chatterjee, Lisa Vermunt, Brian A Gordon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Page
of 2